Fig. 6

Siglec-E downregulates CD36-mediated signaling. a WT peritoneal macrophages were treated with oxLDL (50 μg/ml) for indicated times. Cell lysates were prepared, followed by immunoprecipitation with anti-Siglec E antibody. The immunoprecipitates were then subjected to Western blot analysis with indicated antibodies and analyzed by densitometry. The value at zero time point was referred to 1. The quantitative data are mean ± SE of 3 independent experiments. *P < 0.05 vs zero time point. b WT and SE^−/− macrophages were treated with oxLDL (50 μg/ml) for indicated times, and the cell lysates were analyzed by Western blotting with anti-phosphoVAV and VAV antibodies and analyzed by densitometry. The value at zero time point was referred to 1. The quantitative data are mean ± SE of 3 independent experiments. *P < 0.05 vs WT group at the same time point. c The cell lysates prepared from WT and SE^−/− macrophages treated with oxLDL for indicated times as described above were subjected to immunoprecipitation with anti-VAV antibody. The immunoprecipitates were subjected to Western blot analysis with indicated antibodies and analyzed by densitometry. The value at zero time point was referred to 1. The quantitative data showing relative SHP-1/VAV are mean ± SE of 3 independent experiments. *P < 0.05 vs WT group at the same time point. d WT and SE^−/− macrophages were pretreated with 10 µM of NSC87877 for 30 min in culture, followed by incubation with Dil-oxLDL (10 μg/ml) for another 1 h. The accumulation of intracellular Dil-oxLDL was examined by confocal microscopy. e The quantitative results of (d). Data shown are the mean ± SE of 3 independent experiments. *P < 0.05 vs untreated WT cells; ^ƗP < 0.05 vs untreated WT cells